EVMN
Evommune Inc
NYSE · Biotechnology
$17.31
+0.65 (+3.90%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 7.34M | 78.02M | 75.69M | 85.24M |
| Net Income | -70,021,317 | -16,723,517 | -20,379,208 | -23,619,828 |
| EPS | — | — | — | — |
| Profit Margin | -954.4% | -21.4% | -26.9% | -27.7% |
| Rev Growth | — | -7.7% | +21.3% | +18.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 47.33M | 82.29M | 83.85M | 90.36M |
| Total Equity | 225.51M | 243.06M | 274.02M | 233.46M |
| D/E Ratio | 0.21 | 0.34 | 0.31 | 0.39 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -72,070,384 | -28,105,243 | -27,281,553 | -29,215,509 |
| Free Cash Flow | — | -11,355,754 | -12,035,038 | -9,988,803 |